Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer
Supriya Chopra(Tata Memorial Hospital), Cynthia Ménard(University of Toronto), Gerard Morton(Sunnybrook Health Science Centre), Robert G. Bristow(Princess Margaret Cancer Centre), Ants Toi, Andrew Evans(University of Dundee), Andrew Bayley(University Health Network), Nathan Taback(Ontario Institute for Cancer Research), Michael Milosevic(Princess Margaret Cancer Centre), Danny Vesprini(Sunnybrook Health Science Centre), Peter Chung(Princess Margaret Cancer Centre), Charles Catton(University of Toronto), Masoom A. Haider(Princess Margaret Cancer Centre), Padraig Warde(University Health Network)
International Journal of Radiation Oncology*Biology*Physics
January 30, 2012
Cited by 60
Related Papers
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
|New England Journal of Medicine|1997|1.6k
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Cardiac tumours: diagnosis and management
|The Lancet Oncology|2005|848
Federated learning for predicting clinical outcomes in patients with COVID-19
|Nature Medicine|2021|760